Sverige - svenska - Läkemedelsverket (Medical Products Agency)

amring farma srl - melfalanhydroklorid - pulver och vätska till injektions-/infusionsvätska, lösning - 50 mg - melfalanhydroklorid 55,97 mg aktiv substans; etanol, vattenfri hjälpämne; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - melfalanhydroklorid - pulver och vätska till injektions-/infusionsvätska, lösning - 50 mg - propylenglykol hjälpämne; melfalanhydroklorid 55,97 mg aktiv substans; etanol, vattenfri hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

macure pharma aps - melfalanhydroklorid - pulver och vätska till injektions-/infusionsvätska, lösning - 50 mg - melfalanhydroklorid 55,973 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiska medel - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Europeiska unionen - svenska - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multipelt myelom - antineoplastiska medel - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - melfalanhydroklorid - pulver och vätska till injektions-/infusionsvätska, lösning - 50 mg - melfalanhydroklorid 55,96 mg aktiv substans; etanol, vattenfri hjälpämne; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aspen pharma trading limited - melfalan - filmdragerad tablett - 2 mg - melfalan 2 mg aktiv substans - melfalan

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - melfalan - filmdragerad tablett - 2 mg - melfalan 2 mg aktiv substans - melfalan

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - melfalan - filmdragerad tablett - 2 mg - melfalan 2 mg aktiv substans - melfalan

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - melfalan - filmdragerad tablett - 2 mg - melfalan 2 mg aktiv substans - melfalan